Cat Vaccines Market Size & Share 2026-2035

Cat Vaccines Market Size

The cat vaccines market was valued at USD 1.5 billion in 2025. The market is expected to grow from USD 1.6 billion in 2026 to USD 3.1 billion in 2035, growing at a CAGR of 7.6% during the forecast period, as per the latest report published by Global Market Insights Inc.

Vaccination is crucial for protecting cats against various diseases like feline leukemia, feline panleukopenia, feline respiratory diseases, and rabies, which are prevalent in both domestic and stray cats. As more pet owners recognize the importance of preventive healthcare for their cats, the demand for vaccines has surged. Additionally, the increasing focus on zoonotic diseases, which can be transmitted between animals and humans, has led to heightened awareness about the necessity of vaccinations in preventing such diseases, especially rabies. Thus, these factors are collectively contributing to the increased adoption of companion animal vaccines, including cat vaccines, thereby driving the market growth. Moreover, the increased adoption of pet insurance and pet care products and services further support market expansion.

Cat vaccines are a subset of animal vaccines designed to protect companion animals, particularly cats, from various infectious diseases. These vaccines include those for feline leukemia, feline panleukopenia, and feline respiratory diseases as well as vaccines for other critical diseases like rabies. By stimulating the immune system, cat vaccines help prevent the spread of these diseases, ensuring the health and well-being of domestic and outdoor cats.

The top 5 key players in the global cat vaccines market include Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, and Virbac, which collectively hold a significant share of the veterinary vaccines industry due to their extensive companion animal vaccine portfolios and global distribution networks. These companies play a critical role in the market by developing and commercializing vaccines for key feline diseases such as rabies, feline leukemia virus (FeLV), and FVRCP, while investing heavily in R&D and regulatory approvals to improve vaccine efficacy, safety, and global accessibility.

Cat Vaccines Market Trends

• Increasing pet ownership and rising expenditure on pet health are key trends driving the growth of the cat vaccines industry.

• Approximately 370 million households worldwide own a cat, making feline companions one of the most popular pets across continents. This reflects the growing pet ownership trend, particularly in urban environments where cats are favored for their independence and low space requirements.
• As more people consider cats part of their family, they invest in preventive healthcare to ensure the well-being of their cats. This includes regular vaccination and routine testing to protect against diseases such as feline leukemia and rabies.
• Additionally, as per the Humane Society of Huron Valley, spending on cat health is also rising, with owners typically spending between USD 65 –150 annually for vaccines and check-ups, and potentially up to an additional USD 350 for outdoor cats who require more comprehensive care such as heartworm prevention, flea/tick preventatives, and additional vaccinations.
• This trend of rising spending reflects a greater awareness of pet health needs and a growing willingness to invest in preventive measures. Thus, the demand for comprehensive vaccine options is steadily increasing, thereby fueling the growth of the cat vaccines market.
• The rapid growth of veterinary clinics, pet hospitals, and animal healthcare services is another major trend supporting the market. Improved veterinary infrastructure enables easier access to vaccination services and strengthens routine immunization programs. In addition, better veterinary awareness campaigns and diagnostic capabilities are helping detect diseases early and encourage vaccination among pet owners.

Cat Vaccines Market Analysis

Based on the vaccine type, the global market is segmented into modified/attenuated live, inactivated, and other vaccine types. The modified/attenuated live segment accounted for the highest market share of 50.5% in 2025.

• High growth of the segment is primarily driven by its high efficacy, robust immune response, and cost-effectiveness, making it a top choice for veterinarians and pet owners.
• Additionally, these vaccines provide strong, long-lasting immunity against severe and prevalent feline diseases like feline leukemia, feline panleukopenia, and feline respiratory diseases, thereby driving their adoption.
• Moreover, their rapid onset of immunity is especially valuable in high-risk settings, such as shelters, where disease can spread quickly, helping meet the rising demand for effective, convenient preventive care in cats.
• The inactivated vaccine segment, on the other hand, is expected to grow at a CAGR of 7.9% over the analysis period, driven by their strong safety profile, longer shelf life, and widespread use in the prevention of feline diseases such as rabies and feline leukemia.

Based on the disease type, the global cat vaccines market is categorized into feline leukemia, feline panleukopenia (feline distemper), feline respiratory diseases, feline rabies, and other disease types. The feline respiratory diseases segment dominated the market and was valued at USD 500.4 million in 2025.

• Feline respiratory diseases, including Feline Herpesvirus (FHV) and Feline Calicivirus (FCV), are highly contagious and common among cats, especially in multi-cat environments like shelters.
• For instance, as per data published by PetMD, feline herpes is very common in cats, with over 90% of the cat population being exposed at some point in their life. Similarly, FCV occurs most commonly in multi-cat environments. A cat’s risk of exposure is higher in shelters, pet stores, and catteries, where 25 to 40 percent of cats may be carriers.
• These diseases cause severe symptoms, such as breathing difficulties, fever, and reduced appetite, with risks of chronic complications, driving strong demand for preventive vaccines to ensure long-term feline health.
• The combination of high prevalence, serious health impact, and focus on preventive care has led the respiratory diseases segment to dominate the cat vaccines market.
• The feline leukemia segment held the second-highest market share of 28% in 2025, driven by the high prevalence of feline leukemia virus (FeLV) infections and the increasing adoption of vaccination programs to prevent the disease among domestic and shelter cats.

Based on the route of administration, the global cat vaccines market is divided injectables and intranasal. The injectables segment held the highest market share of 70.8% in 2025.

• The injectable vaccines segment dominated the market mainly due to the effectiveness of these vaccines, their historical usage in veterinary practice, and the preference for injectable vaccines among veterinarians for routine immunization.
• Injectable vaccines are commonly used for the prevention of major feline infectious diseases like rabies, feline panleukopenia, feline calicivirus, and feline leukemia virus.
• In addition, the historical regulatory approvals for injectable vaccines, the availability of combination vaccines, and the consistency of their immunological response has contributed to their usage in veterinary clinics and animal hospitals.
• On the other hand, the intranasal vaccines segment is expected to register significant growth at a CAGR of 8.1% over the analysis period, owing to the ability of intranasal vaccines to induce a strong immune response locally in the respiratory tract of the cat and offer quick immunity against respiratory infections. The non-invasive route of administration also helps to minimize stress for the animal and increases the ease of vaccination.

Based on the component, the global cat vaccines market is classified into combined vaccine and mono vaccine. The combined vaccines segment dominated the market with USD 899.4 million in revenue in 2025.

• The combined (multivalent) vaccines segment holds a considerable market share in the market, as these vaccines offer protection against several cat diseases, including feline viral rhinotracheitis, calicivirus, and panleukopenia, in a single dose.
• The ability of these vaccines to reduce the number of injections required, increase vaccination compliance, and simplify vaccination regimens for both veterinarians and pet owners has led to their widespread adoption in veterinary clinics and animal hospitals.

Based on the duration of immunity, the global cat vaccines market is segmented into 1-year, 3-years, and other durations of immunity. The 1-year segment is expected to reach USD 1.5 billion in 2035.

• The 1-year duration segment holds a considerable share of the market as many of the vaccines are designed to last for one year. Therefore, booster shots are to be administered annually.
• Also, several veterinary association guidelines recommend annual revaccinations for various diseases such as feline leukemia and rabies.
• This also helps to keep the pet owners compliant with the vaccination program, as annual vaccination helps to keep track of the overall well-being of the pet while also providing immunity against infectious diseases.
• Moreover, the widespread availability of 1-year vaccine formulations from major manufacturers and their cost-effectiveness compared to longer-duration vaccines further support their adoption.

North America Cat Vaccines Market

North America dominated the global cat vaccines industry in 2025 with a market share of 45.2% and is expected to witness growth at a CAGR of 7.3% over the analysis period.

• North America holds a strong market share in the cat vaccines industry, primarily due to the high rate of pet ownership in the region, coupled with high awareness and adoption of preventive pet care.
• Countries such as the U.S. and Canada have a strong veterinary healthcare system, including a high number of veterinary clinics, pet hospitals, and pet vaccination programs that increase the adoption of cat vaccines.
• In addition, the presence of several animal health companies in the region, high adoption of pet insurance, and a high pet expenditure also contribute to the strong market presence of North America in the cat vaccines industry.

The U.S. cat vaccines market was valued at USD 464.5 million and USD 505.6 million in 2022 and 2023, respectively. The market size reached USD 592.9 million in 2025, growing from USD 547.3 million in 2024.

• The country’s large pet-owning population, alongside a strong veterinary infrastructure, contributes to the increasing demand for vaccines to protect cats from common infectious diseases.
• For instance, according to recent data from Worldostats, the U.S. has an estimated pet cat population of 90 million, leading the global pet cat population.
• Additionally, the U.S. benefits from a well-established veterinary infrastructure, ensuring widespread access to veterinary clinics and pet care facilities, further bolstering market growth.

Europe Cat Vaccines Market

The Europe market was valued at USD 413.7 million in 2025.

• Europe is one of the key markets for cat vaccines due to the presence of an already-established veterinary healthcare system.
• Additionally, increased awareness about pet animal healthcare services in the region increases the adoption of vaccination services. Countries such as Germany, France, and the UK have adopted a rigorous vaccination regime to ensure that pet cats are vaccinated against diseases like rabies, feline viral rhinotracheitis, feline calicivirus, and panleukopenia.
• In addition, a large pet cat population is also an advantage for the European cat vaccine market. For instance, as per Statista, the number of cats owned by households in Europe was measured at approximately 108.3 million in 2023. The cat population in Europe had grown from about 84.7 million in 2010. The pet cat population is increasing rapidly due to increased pet humanization and pet healthcare expenditure.
• Lastly, the presence of key players operating in the animal healthcare industry is also an advantage for the Europe cat vaccine market.

The Germany cat vaccines market is anticipated to witness significant growth over the forecast period.

• There is growing awareness among German pet owners about the importance of preventive care, leading to a shift toward regular vaccinations as part of responsible pet ownership.
• Furthermore, Germany’s strict animal health regulations, including mandatory rabies vaccinations in certain regions, have created a regulatory environment that encourages routine vaccine usage.

Asia Pacific Cat Vaccines Market

• Asia Pacific is expected to witness the highest CAGR during the forecast period for the cat vaccines industry, owing to the increasing pet population, as well as the growing trend of keeping cats as pets in countries such as China, Japan, India, and South Korea.
• The increase in disposable income, urbanization, and changing lifestyles are factors that are expected to drive the growth of the cat vaccines market, as more people are willing to spend on the health of their pets.
• Also, increasing veterinary infrastructure and awareness, and the presence of international animal health companies are expected to contribute to the market growth.

China is expected to experience growth at a significant rate during the analysis period.

• As per the Cat Population 2024 by World Population Review, cat ownership is increasingly popular in China, with an estimated 53.1 million cats.
• Cats are highly valued in Chinese culture as symbols of fortune, which further boosts their appeal as companion animals. They are also favored for their low maintenance, quiet nature, and affordability, making them a preferred choice for many households.
• As the pet cat population grows, there is a rising need for vaccinations to protect against common feline diseases, contributing to the demand for cat vaccines in the country.

Latin America Cat Vaccines Market

Brazil's cat vaccines industry is projected to showcase lucrative growth in the Latin America market during the forecast timeframe.

• The market is expected to experience lucrative growth due to a growing pet cat population, which currently stands at around 22.1 million, as per the Cat Population 2024 by World Population Review.
• The popularity of breeds like the Brazilian Shorthair and increasing awareness of pet health have driven demand for vaccinations to protect cats from common diseases.
• Additionally, expanding veterinary care infrastructure and the overall growth of Brazil's pet industry, including increased accessibility to pet care services, further contribute to the market's promising growth prospects during the forecast period.

Middle East & Africa Cat Vaccines Market

Saudi Arabia market is poised to grow in the coming years.

• The Saudi government’s focus on improving veterinary care and animal welfare contributes to market expansion, along with growing investments in veterinary clinics and hospitals offering specialized services for pets.
• Additionally, the increasing availability of advanced vaccine options and a rising trend toward regular veterinary checkups are fueling market growth in Saudi Arabia.

Cat Vaccines Market Share

The cat vaccines industry is highly competitive, with prominent players like Merck, Zoetis, Boehringer Ingelheim, Virbac, and Elanco leading the industry. The top 5 players account for ~68.4% of the global market. Key market strategies include expanding product portfolios, with a focus on innovative formulations such as combined vaccines, which provide protection against multiple diseases with a single dose, and vaccines offering extended immunity durations. Additionally, emerging markets with growing awareness of pet healthcare are becoming key areas for expansion.

Cat Vaccines Market Companies

Few of the prominent players operating in the cat vaccines industry include:

• Bioveta
• Boehringer Ingelheim
• Ceva Santé Animale
• Elanco Animal Health
• HIPRA
• Indian Immunologicals
• Merck
• Virbac
• Zoetis

• Zoetis

Zoetis is one of the leading players in the cat vaccines market, supported by its broad companion animal vaccine portfolio and strong global veterinary distribution network. The company offers vaccines such as Fel-O-Vax, FelineGuard, and Fevac, which protect against major diseases, including panleukopenia, herpesvirus, and calicivirus, strengthening its position in preventive animal healthcare.

• Boehringer Ingelheim

Boehringer Ingelheim holds a strong position in the cat vaccines market through its PUREVAX portfolio, which includes non-adjuvanted vaccines designed specifically for cats. These vaccines use innovative recombinant technology to provide protection against diseases such as feline leukemia and rabies while improving safety and immune responses in feline patients.

Cat Vaccines Industry News

• In September 2024, Merck Animal Health announced the expansion of its NOBIVAC NXT platform with the launch of the first and only RNA-particle technology vaccine for Feline leukemia virus (FeLV). This innovation helps strengthen the company’s leadership in the feline vaccine market, offering an advanced solution to meet the growing demand for effective feline leukemia prevention.
• In June 2024, Merck Animal Health announced the launch of its NOBIVAC NXT Rabies portfolio in Canada, which includes NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies, reaffirming the company's commitment to rabies protection. The company benefits from expanding its product offerings in Canada, enhancing its position as a leader in rabies prevention for both cats and dogs.

The cat vaccines market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Modified/attenuated live
• Inactivated
• Other vaccine types

Market, By Disease Type

• Feline respiratory diseases
• Feline leukemia
• Feline panleukopenia (feline distemper)
• Feline rabies
• Other disease types

Market, By Route of Administration

• Injectables
• Intranasal

Market, By Component

• Combined vaccine
• Mono vaccine

Market, By Duration of Immunity

• 1-year
• 3-years
• Other durations of immunity

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE